Successful Treatment of
            <i>Saksenaea</i>
            sp. Osteomyelitis by Conservative Surgery and Intradiaphyseal Incorporation of Amphotericin B Cement Beads

Parize, Perrine; Mamez, Anne‐Claire; García-Hermoso, Dea; Dumaine, Valérie; Poirée, S.; Kauffmann‐Lacroix, C.; Jullien, Vincent; Lortholary, Olivier

doi:10.1128/aac.01006-18

Cited by 8 publications

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is interesting to note that amphotericin B, a drug that is being the first choice for treatment of mucormycoses (2) including those caused by the Saksenaea species (e.g. (6–9), showed only very weak activity against S. dorisiae . From the azoles used in the study, ketoconazole, posaconazole and itraconazole showed weak activity at rather high minimum effective concentrations, i.e.…”

Section: Discussionmentioning

confidence: 99%

A New European Species of The Opportunistic Pathogenic GenusSaksenaea–S. dorisiaeSp. Nov.

Labuda

Bernreiter

Hochenauer

et al. 2019

Preprint

View full text Add to dashboard Cite

A new species Saksenaea dorisiae (Mucoromycotina, Mucorales), recently isolated 18 from a water sample originating from a private well in a rural area of Serbia (Europe), is 19 described and illustrated. The new taxon is well supported by phylogenetic analysis of the 20 internal transcribed spacer region (ITS), domains D1 and D2 of the 28S rRNA gene (LSU), and 21 translation elongation factor-1α gene (TEF-1α), and it is resolved in a clade with S. 22 oblongispora and S. trapezispora. This fungus is characteristic by its moderately slow growth 23 at 15 and 37°C, sparse rhizoids, conical-shaped sporangia and short-cylindrical 24 sporangiospores. S. dorisiae is a member of the opportunistic pathogenic genus often 25 involved in severe human and animal mucormycoses encountered in tropical and subtropical 26 regions. Despite its sensitivity to several conventional antifungals (terbinafine and 27 ciclopirox), the fungus is potentially causing clinically challenging infections. This is the first 28 novel taxon of the genus Saksenaea described from the moderately continental climate area 29 of Europe.30

show abstract

Section: Discussionmentioning

confidence: 99%

A New European Species of The Opportunistic Pathogenic GenusSaksenaea–S. dorisiaeSp. Nov.

Labuda

Bernreiter

Hochenauer

et al. 2019

Preprint

View full text Add to dashboard Cite

show abstract

“…New topical formulations, like aerosolized L-AmB, show promise for local intrapulmonary drug delivery, decreasing systemic absorption and improving survival when administered early. There are anecdotal reports on the use of AmB eye drops for keratitis, oral AmB for gastrointestinal mucormycosis, intradiaphyseal incorporation cement beads in osteomyelitis, intrathecal administration in cerebral abscess, and percutaneous injection in cutaneous lesions [7,[70][71][72][73][74]. The optimal usage of these formulations in conjunction with systemic therapy is yet to be determined [7].…”

Section: Management Of Mucormycosismentioning

confidence: 99%

From Spores to Solutions: A Comprehensive Narrative Review on Mucormycosis

Gullì,

Hallur,

Kale

et al. 2024

Diagnostics

View full text Add to dashboard Cite

Mucormycosis is an infrequent but fatal illness that mainly affects patients with uncontrolled diabetes mellitus, diabetic ketoacidosis, solid and hematologic neoplasms, organ transplantation, chronic steroid intake, prolonged neutropenia, iron overload states, neonatal prematurity, severe malnutrition, and HIV. Many cases were reported across the world recently following the COVID-19 pandemic. Recent research has led to a better understanding of the pathogenesis of the disease, and global guidelines are now available for managing this serious infection. Herein, we comprehensively review the etiological agents, pathogenesis, clinical presentations, diagnosis, and management of mucormycosis.

show abstract

“…Furthermore, rhino-orbito-cerebral and disseminated infections have been reported [1, 2]. Classic management of the infection site usually includes a combination of broad, aggressive and repeated surgical debridement (which may lead to amputation), and long-term systemic therapy with appropriate antifungals, preferably liposomal amphotericin B and/or posaconazole [6–9]. Antifungal therapy alone seems to be inadequate to control infection [2].…”

Section: Introductionmentioning

confidence: 99%

Saksenaea dorisiaesp. nov., a New Opportunistic Pathogenic Fungus from Europe

Labuda

Bernreiter

Hochenauer

et al. 2019

International Journal of Microbiology

View full text Add to dashboard Cite

A new species, Saksenaea dorisiae (Mucoromycotina, Mucorales), isolated from a water sample originating from a private well in Manastirica, Petrovac, in the Republic of Serbia (Europe), is described and illustrated. The new taxon is well supported by multilocus phylogenetic analysis that included the internal transcribed spacer (ITS) region, domains D1 and D2 of the 28S rRNA gene (LSU), and translation elongation factor-1α gene (tef-1α), and it is resolved in a clade with S. oblongispora and S. trapezispora. This fungus is characterized by its moderately slow growth at 15 and 37°C, sparse rhizoids, conical-shaped sporangia, and short-cylindrical sporangiospores. Saksenaea dorisiae is a member of the opportunistic pathogenic genus often involved in severe human and animal mucormycoses encountered in tropical and subtropical regions. Despite its sensitivity to several conventional antifungals (terbinafine and ciclopirox), the fungus can potentially evoke clinically challenging infections. This is the first novel taxon of the genus Saksenaea described from the moderately continental climate area of Europe.

show abstract

Successful Treatment of Saksenaea sp. Osteomyelitis by Conservative Surgery and Intradiaphyseal Incorporation of Amphotericin B Cement Beads

Cited by 8 publications

References 19 publications

A New European Species of The Opportunistic Pathogenic GenusSaksenaea–S. dorisiaeSp. Nov.

A New European Species of The Opportunistic Pathogenic GenusSaksenaea–S. dorisiaeSp. Nov.

From Spores to Solutions: A Comprehensive Narrative Review on Mucormycosis

Saksenaea dorisiaesp. nov., a New Opportunistic Pathogenic Fungus from Europe

Contact Info

Product

Resources

About